Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;15(3):224-31.
doi: 10.1007/s11912-013-0306-8.

Novel immunotherapies in GU malignancies

Alexandra Drakaki  1 , David F McDermott
Affiliations
Review

Novel immunotherapies in GU malignancies

Alexandra Drakaki et al. Curr Oncol Rep. 2013 Jun.

Abstract

Despite the development of several novel therapies in recent years, genitourinary (GU) malignancies remain associated with significant morbidity and mortality. An improved understanding of how the immune system responds to cancer has led to the clinical development of several targeted immunotherapies. Data from recent clinical trials suggests that these agents might improve the prognosis of patients with advanced GU malignancies. This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. J Clin Oncol. 1995 Mar;13(3):688-96 - PubMed
    1. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
    1. Curr Oncol Rep. 2013 Apr;15(2):98-104 - PubMed
    1. J Clin Oncol. 2009 Jul 10;27(20):3312-8 - PubMed
    1. J Clin Oncol. 2010 Jul 1;28(19):3167-75 - PubMed

MeSH terms

LinkOut - more resources